HCR Wealth Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.61M | Buy |
14,341
+166
| +1% | +$35.7K | 0.32% | 49 |
|
|
2026
Q1 | $3.08M | Buy |
14,175
+103
| +0.7% | +$22.8K | 0.32% | 56 |
|
|
2025
Q4 | $3.22M | Buy |
14,072
+4
| +0% | +$911 | 0.32% | 51 |
|
|
2025
Q3 | $3.33M | Sell |
14,068
-243
| -2% | -$49.5K | 0.34% | 49 |
|
|
2025
Q2 | $2.66M | Buy |
14,311
+20
| +0.1% | +$3.72K | 0.31% | 57 |
|
|
2025
Q1 | $2.99M | Buy |
14,291
+56
| +0.4% | +$10.9K | 0.39% | 46 |
|
|
2024
Q4 | $2.53M | Buy |
14,235
+34
| +0.2% | +$6.25K | 0.32% | 53 |
|
|
2024
Q3 | $2.8M | Hold |
14,201
| – | – | 0.37% | 46 |
|
|
2024
Q2 | $2.44M | Sell |
14,201
-87
| -0.6% | -$14.4K | 0.35% | 46 |
|
|
2024
Q1 | $2.6M | Sell |
14,288
-325
| -2% | -$56K | 0.39% | 42 |
|
|
2023
Q4 | $2.26M | Buy |
14,613
+2,356
| +19% | +$343K | 0.36% | 48 |
|
|
2023
Q3 | $1.83M | Sell |
12,257
-3,448
| -22% | -$506K | 0.4% | 45 |
|
|
2023
Q2 | $2.12M | Sell |
15,705
-519
| -3% | -$76.1K | 0.39% | 47 |
|
|
2023
Q1 | $2.59M | Sell |
16,224
-363
| -2% | -$55.5K | 0.51% | 38 |
|
|
2022
Q4 | $2.68M | Sell |
16,587
-503
| -3% | -$77.1K | 0.56% | 34 |
|
|
2022
Q3 | $2.29M | Sell |
17,090
-432
| -2% | -$62K | 0.49% | 41 |
|
|
2022
Q2 | $2.68M | Sell |
17,522
-284
| -2% | -$43.4K | 0.54% | 39 |
|
|
2022
Q1 | $2.89M | Sell |
17,806
-12,762
| -42% | -$1.85M | 0.47% | 46 |
|
|
2021
Q4 | $4.14M | Sell |
30,568
-1,115
| -4% | -$132K | 0.64% | 28 |
|
|
2021
Q3 | $3.42M | Buy |
31,683
+75
| +0.2% | +$8.57K | 0.57% | 34 |
|
|
2021
Q2 | $3.56M | Buy |
31,608
+1,020
| +3% | +$115K | 0.62% | 29 |
|
|
2021
Q1 | $3.31M | Buy |
+30,588
| New | +$3.27M | 0.65% | 29 |
|
|
2020
Q4 | – | Sell |
-30,512
| Closed | -$2.66M | – | 268 |
|
|
2020
Q3 | $2.66M | Buy |
30,512
+484
| +2% | +$45.6K | 0.61% | 28 |
|
|
2020
Q2 | $2.98M | Buy |
+30,028
| New | +$2.64M | 0.7% | 21 |
|
|
2019
Q1 | – | Sell |
-3,409
| Closed | -$295K | – | 172 |
|
|
2018
Q4 | $295K | Buy |
+3,409
| New | +$300K | 0.1% | 129 |
|
|
2018
Q3 | – | Sell |
-3,484
| Closed | -$303K | – | 156 |
|
|
2018
Q2 | $303K | Buy |
3,484
+25
| +0.7% | +$2.44K | 0.1% | 137 |
|
|
2018
Q1 | $308K | Sell |
3,459
-3
| -0.1% | -$330 | 0.11% | 132 |
|
|
2017
Q4 | $315K | Buy |
3,462
+1,104
| +47% | +$104K | 0.11% | 132 |
|
|
2017
Q3 | $210K | Buy |
+2,358
| New | +$179K | 0.09% | 152 |
|
Other funds holding ABBV
HCR Wealth Advisors's ABBV Position: Q2 2026 in Review
HCR Wealth Advisors increased its AbbVie (ABBV) stake by 1.2% in Q2 2026, buying an estimated $35.7K and bringing the position to 14,341 shares worth $3.61M. The position accounts for 0.32% of the portfolio, ranked #49.
HCR Wealth Advisors first reported a position in ABBV in Q3 2017 and has held it in 29 quarters since. The position peaked at $4.14M in Q4 2021. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- HCR Wealth Advisors held 14,341 shares of AbbVie worth $3.61M as of Q2 2026.
- HCR Wealth Advisors bought 166 AbbVie shares in Q2 2026, an estimated $35.7K.
- AbbVie made up 0.32% of HCR Wealth Advisors's portfolio in Q2 2026, its #49 holding.
- HCR Wealth Advisors first reported a position in AbbVie in Q3 2017 and has held it in 29 quarters since.
- HCR Wealth Advisors's AbbVie position peaked at $4.14M in Q4 2021.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on HCR Wealth Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.